Investment Thesis
Protagonist Therapeutics faces severe operational distress with revenue collapsing 89% YoY while burning $48.9M in operating cash annually. Despite a strong balance sheet with $193.7M in cash, deteriorating fundamentals—negative operating margins, persistent cash burn, and minimal returns on assets (0.5%)—indicate the core business is in substantial decline. The company's cash runway of ~4 years provides temporary stability but offers insufficient time to reverse the dramatic top-line contraction without credible turnaround evidence.
Strengths
- Strong balance sheet with $655.5M stockholders' equity and minimal debt ($9.8M)
- Substantial cash reserves of $193.7M providing operational runway
- Exceptional liquidity position (17.76x current ratio) enabling survival through restructuring
Risks
- Catastrophic revenue decline of 89.4% YoY signals loss of key product, partnership termination, or clinical failure
- Negative operating cash flow of -$48.9M with no clear path to profitability in disclosed metrics
- Operating margin of -6.5% combined with minimal ROE (0.6%) and ROA (0.5%) indicates fundamental business model stress
- Cash depletion timeline (~4 years at current burn rate) creates existential pressure without revenue stabilization
Key Metrics to Watch
- Quarterly revenue trend and stabilization signals
- Operating cash flow inflection point toward positive territory
- Gross margin and operating leverage recovery metrics
- Cash burn rate trajectory and runway extension milestones
Financial Metrics
Revenue
56.4M
Net Income
3.8M
EPS (Diluted)
$0.05
Free Cash Flow
-49.2M
Total Assets
697.5M
Cash
193.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-6.5%
Net Margin
6.7%
ROE
0.6%
ROA
0.5%
FCF Margin
-87.2%
Balance Sheet & Liquidity
Current Ratio
17.76x
Quick Ratio
17.76x
Debt/Equity
0.01x
Debt/Assets
6.0%
Interest Coverage
-6.10x
Long-term Debt
9.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:16:29.659225 |
Data as of: 2026-03-31 |
Powered by Claude AI